Market Analysis

The pulmonary edema market is expected to reach USD 11.2 Billion by 2030 at 7.10% CAGR during the forecast period 2022-2030. Pulmonary edema is a medical condition that takes place when fluid gets accumulated in the air sacs of the lungs called the alveoli which results in the difficulty to breathe. It interferes with the gas exchange thereby resulting in respiratory failure. Pulmonary edema has some alternate names- pulmonary congestion, lung water or lung congestion. It is of two types namely acute or sudden onset and chronic that occurs gradually over time. The acute pulmonary edema symptoms include shortness of breath accompanied with wheezing and coughing (that often produces frothy, pink sputum). Here the treatment will vary resting on the severity. However, medications and supplemental oxygen mount the backgrounds in most pulmonary edema treatment methods. 

There are many factors that is driving the growth of the pulmonary edema market. Some of these factors as per the Market Research Future (MRFR) report include rising prevalence of pulmonary edema as well as diseases such as heart disease, kidney failure and others, growing geriatric population, changing lifestyles, extensive R&D activities and growing awareness regarding preventive therapies. On the contrary, lack of awareness regarding the disease and low per capita healthcare cost in the low and middle-income countries are estimated in hampering the growth of the pulmonary edema market. 

Key Players 

Leading players profiled in the pulmonary edema market include Canon Medical Systems Corporation (Japan), Hitachi Medical Corporation (U.S.), Siemens Healthcare GmbH (Germany), Koninklijke Philips N.V. (The Netherlands), Medtronic (U.S.), Vitaltec Corporation (China), Lupin Pharmaceuticals, Inc. (India), Alcaliber S.A. (Spain), BD (U.S.), Edwards Lifesciences Corporation (U.S), ARGON MEDICAL (U.S.), and Pfizer Inc. (U.S.).

Market Segmentation

Market Research Future report offers an all-inclusive segmental analysis of the pulmonary edema market on the basis of type, diagnosis, treatment and end-user. 

Based on type, it is segmented into cardiogenic edema and others. 

Based on diagnosis, the pulmonary edema market is segmented into imaging, blood tests and others. The blood test is further segmented into kidney function test, blood count test and b-type natriuretic peptide (BNP) and others. The imaging segment is further segmented into pulse oximetry, transesophageal echocardiography, echocardiogram, electrocardiogram and chest x-ray. 

Based on treatment, it is segmented into suction catheter, morphine, preload reducers and others. The preload reducers are further segmented into diuretics, nitroglycerin and others. 

Based on end users, the pulmonary edema market is segmented into retail pharmacies, academic institutes, hospitals and clinics and others. 

Regional Analyis 

Based on region, the pulmonary edema market report covers growth opportunities and latest trends across North America, Europe, Asia Pacific and the Middle East and Africa. Of these, North America will rule the market due to high per capita healthcare cost and a healthcare sector that is well-developed. Besides, the existence of developed economies such as Canada and the US and the presence of some global players here is anticipated to drive the growth of the pulmonary edema market in this region. 

Europe holds the second biggest share followed by the APAC region. The factors that have contributed to the growth of the market in Europe include the accessibility of funds for research and the existence of developed economies such as Germany, Italy and France in this region. Besides, the rising geriatric population here will further drive the growth of the market. 

The market in the APAC region is the fastest growing owing to the existence of developing economies such as China and India here. Besides, increasing healthcare expenditure coupled with favorable government policies will fuel the growth of the pulmonary edema market. The Indian healthcare sector is the largest with regards to employment and revenue, as stated by the Indian Brand Equity Foundation, 2018. Besides, the industry is anticipated to expand at a stellar rate due to rising expenditure by both private and public players. The Middle East and Africa has a minimum share. The existence of poor economies particularly in the African region is what makes the pulmonary edema market to lag. The Middle East will account for a good share in the Middle East and Africa region owing to massive healthcare cost due to the existence of developed economies such as Qatar, Kuwait, and Saudi Arabia in the region. 

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013,

United States of America